Macrophage pyroptosis drives luminal senescence and club-cell reprogramming in 5α-reductase inhibitor-treated prostatic hyperplasia.

Zheng Li, Zhenan Zhang, Qiancheng Zhao, Zhenpeng Zhu, Kaiwei Yang, Yisen Meng, Qian Zhang, Wei Yu

Abstract read

In one paragraph

Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zheng Li *Department of Urology, Peking University First Hospital, Institute of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center., National Research Center for Genitourinary Oncology, Peking University, Beijing, China.

Zhenan Zhang *Department of Urology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Qiancheng Zhao *Department of Urology, Peking University First Hospital, Institute of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center., National Research Center for Genitourinary Oncology, Peking University, Beijing, China.

Zhenpeng Zhu *Department of Urology, Peking University First Hospital, Institute of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center., National Research Center for Genitourinary Oncology, Peking University, Beijing, China.

Kaiwei YangDepartment of Urology, Peking University First Hospital, Institute of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center., National Research Center for Genitourinary Oncology, Peking University, Beijing, China.

Yisen MengDepartment of Urology, Peking University First Hospital, Institute of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center., National Research Center for Genitourinary Oncology, Peking University, Beijing, China. mgyss@qq.com.

Qian ZhangDepartment of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. zhangqianbjmu@126.com.

Wei YuDepartment of Urology, Peking University First Hospital, Institute of Urology, Beijing Key Laboratory of Urogenital Diseases (Male), Molecular Diagnosis and Treatment Center., National Research Center for Genitourinary Oncology, Peking University, Beijing, China. yuweipku@bjmu.edu.cn.ORCID http://orcid.org/0000-0002-0938-0308

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benign prostatic hyperplasia (BPH) is a common age-associated disease whose prevalence rises sharply with advancing age. Therapeutic responses to 5α-reductase inhibitors (5-ARIs) in BPH are heterogeneous and may ultimately culminate in the need for surgery; however, the mechanisms that permit disease progression during treatment remain unclear. Here we integrate spatial and single-cell transcriptomics with functional perturbations and mouse genetics to delineate a macrophage-orchestrated pyroptosis-senescence-club axis in the human prostate. In 5-ARI-exposed tissue, we observe enrichment of cleaved-GSDMD⁺ macrophages, elevated epithelial p16

Identifiers

PMID42844351

DOI10.1016/S1470-2045(20)30458-7

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.